Table 3. Response of C26-B and C26-10 tumours to 5-FU treatment with or without carbogen breathing.

Tumour	(Group) Treatmenta	n	TDb (days)	GDFc	WL (%)d	n
C26-B	Controls		2.9±1.1
	(1) 5-FU	9	10.2 (6.9, 17.1)	2.52	5.6±8.4	10
	(2) 5-FU+carbogen	11	10.2 (6.9, 19.6)	2.52	11.1±5.7	11
C26-10	Controls		4.1±2.6
	(3) 5-FU	11	13.3 (9.3, >28)	2.23	11.9±8.3	13
	(4) 5-FU+carbogen	10	>28 (9, >28)	>5.83	11.1±3.3	10

^aThe Group number corresponds to the labelling in Figure 2.

^bTumour doubling time is presented as mean±s.d. for untreated historical controls or as median (min, max) measured from treatment day 0 (excluding mice with<three observations). The symbol>indicates that doubling did not occur before the end of the experiment on day 28. One C26-10 tumour treated with 5-FU and one C26-10 tumour treated with 5-FU+carbogen showed complete remission. Significance of comparisons (Wilcoxon rank-sum test): (1) vs (3) P=0.048; (2) vs (4) P=0.002; (1) vs (2) P=0.62; (3) vs (4) p=0.033.

^cGrowth delay factor (see Materials and Methods).

^dMean weight loss per time point (see Materials and Methods) (mean±s.d., including mice with<three observations).